Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 8/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 3/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15744687 | 0.88 | APLNR (0.40) | APLNRCAPN1 | |
| SCHEMBL15745525 | 0.82 | APLNR (0.36) | GRPRAPLNR | |
| SCHEMBL26403817 | 0.82 | MMP3 (0.42) | GRPRESR1ESR2SLC15A2APLNR | |
| SCHEMBL19084162 | 0.82 | APLNR (0.36) | APLNRCAPN1 | |
| SCHEMBL13624749 | 0.78 | CTSS (0.48) | CAPN1 | |
| SCHEMBL14399315 | 0.78 | CTSS (0.48) | CAPN1 | |
| SCHEMBL2623712 | 0.77 | APLNR (0.40) | APLNRCAPN1 | |
| SCHEMBL18672489 | 0.76 | ESR1 (0.52) | ESR1ESR2SLC15A2 | |
| SCHEMBL14439383 | 0.73 | CTSS (0.43) | CAPN1 | |
| SCHEMBL15185930 | 0.72 | GRPR (0.50) | GRPRSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780833-B2 | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | HOWARD UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780833-B2 | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | EML4, MCL1, ERAP2 | GRPR 2713/4885ESR1 27/4885ESR2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.